Back
Protalix BioTherapeutics 10K Form
Buy
68
PLX
Protalix BioTherapeutics
Last Price:
1.27
Seasonality Move:
64.55%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive PLX News And Ratings
See the #1 stock for the next 7 days that we like better than PLX
PLX Financial Statistics
Sales & Book Value
Annual Sales: | $65.49M |
---|---|
Cash Flow: | $-3.78M |
Price / Cash Flow: | 0 |
Annual Sales: | $0.39 |
Price / Book: | 3.22 |
Profitability
EPS (TTM): | -0.23000 |
---|---|
Net Income (TTM): | $-14.69M |
Gross Margin: | $42.51M |
Return on Equity: | -43.43% |
Return on Assets: | -16.63% |
Protalix BioTherapeutics Earnings Forecast
Key Protalix BioTherapeutics Financial Ratios
- The Gross Profit Margin over the past 26 years for PLX is 64.91%.
- The Selling, General & Administrative Expenses for PLX have been equal to 22.84% of Gross Profit Margin.
- The Research & Development expenses have been 26.10% of Revenue.
- The Interest Expense is 38.26% of Operating Income.
- The Net Earning history of PLX is 12.69% of Total Revenues.
- Per Share Earnings over the last 28 years have been positive in 13 years.
Protalix BioTherapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYAM |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | PLX |
CUSIP: | 74365A |
Website: | protalix.com |
Debt
Debt-to-Equity Ratio: | 0.71 |
---|---|
Current Ratio: | 1.33 |
Quick Ratio: | 0.95 |
Price-to-Earnings
Trailing P/E Ratio: | 13.89 |
---|---|
Forward P/E Ratio: | 0 |
PLX Technical Analysis vs Fundamental Analysis
Buy
68
Protalix BioTherapeutics (PLX)
is a Buy
Is Protalix BioTherapeutics a Buy or a Sell?
-
Protalix BioTherapeutics stock is rated a Buy
The current Protalix BioTherapeutics [PLX] share price is $1.25. The Score for PLX is 68, which is 36% above its historic median score of 50, and infers lower risk than normal.